Tag Archives: GLP-1 side effects

The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability. Why do some patients tolerate GLP-1 receptor agonists with ease while others discontinue early? Much like how individuals respond differently to diet or exercise, medication tolerance is influenced by a mix …

GLP-1 dose escalation is quickly becoming a central topic in diabetes care, especially as higher dosing strategies gain traction. But are we truly entering a high-dose era, or simply refining how we use these powerful agents? As clinicians face patients who plateau on standard regimens, the question becomes not just …

GLP-1 dose escalation is becoming a critical topic as demand for these therapies continues to surge. From semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro), these medications are reshaping diabetes and weight management. However, are clinicians and patients moving faster than the evidence supports? As real-world practices evolve, dosing strategies often stray …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity. However, one question clinicians increasingly ask is whether gastric motility adapts during long-term GLP-1 therapy. These medications slow gastric emptying, which contributes to appetite control and postprandial glucose reduction. Yet the human body often …

GLP‑1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss. But as more patients stay on these medications for years—not just months—questions around GLP‑1 long‑term safety have become essential to address. From gastrointestinal discomfort to gallbladder risks and …

When managing type 2 diabetes, most decisions around treatment focus on blood sugar control and cardiovascular outcomes. But what about how patients feel day to day? The diabetes medications quality of life—including side effects like fatigue, gastrointestinal issues, and medication burden—often gets overlooked. Yet, these symptoms directly impact a patient’s …